Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Sulagna Banerjee
University of Miami School of Medicine, Department: Surgery
Should you be removed from our database? Contact us at [email protected]. Read more below.
Minneamrita Therapeutics
Salary not from the awardee Institution
Dr. Banerjee is a compensated consultant for Minneamrita, which directly overlaps with her sponsored research.
Triptolide Augments Death Receptor Mediated Apoptosis in Pancreatic Cancer
Pancreatic cancer is resistant to conventional as well as novel anti-cancer therapies including TRAIL (Tumor Necrosis Factor-Related Apoptosis Inducing Ligand). Studies in our laboratories show that triptolide, a compound isolated from the Chinese plant Tripterygium wilfordii, sensitizes pancreatic cancer cells to cell death caused by TRAIL. In the current grant proposal, we intend to confirm the efficacy of the combination of TRAIL and triptolide against pancreatic cancer in animal models of pancreatic cancer, and investigate the mechanism of action of this combined therapy. Once unraveled, the mechanisms by which triptolide sensitizes pancreatic cancer cells to TRAIL will lead to the development of novel drug targets. Successful completion of these mechanistic and translational studies will eventually help in planning strategies to combine triptolide with TRAIL so that this combination can be used for the treatment of pancreatic cancer.
Filed on August 03, 2016.
Tell us what you know about Sulagna Banerjee's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Sulagna Banerjee”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Sulagna Banerjee | University of Miami School of Medicine | Conflict of Interest | Minneamrita Therapeutics | $10,000 - $19,999 |
| Sulagna Banerjee | University of Miami School of Medicine | Conflict of Interest | Minneamrita Therapeutics | $10,000 - $19,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.